Ignite Creation Date:
2024-05-06 @ 2:38 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04373967
Status:
UNKNOWN
Last Update Posted:
2020-07-08
First Post:
2020-04-28
Brief Title:
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase IIIRandomizedParallelOpen-labelMulticenter Trial to Compare the Efficacy and Safety of Liraglutide and Victoza in Patients With Type 2 Diabetes Inadequately Controlled by Oral Metformin Alone
Status:
UNKNOWN
Status Verified Date:
2020-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Liraglutide injection is a glucagon-like peptide-1 GLP-1 analogue that activates the cyclic adenosine monophosphate cAMP and mitogen-activated protein kinase MAPK pathway by binding to the GLP-1 receptor GLP-1Rthusit has physiological effects such as glucose-dependent insulin synthesis and secretion inhibition of β-cell apoptosis promotion of β-cell proliferation and regeneration inhibition of glucagon secretion reduction of food intake delay of gastric emptying enhancement of glucose utilization in peripheral tissues and reduction of glycogen output Liraglutide injectiondeveloped and marketed as Victoza by Novo Nordiskis indicated for the treatment of patients with type 2 diabetes and was approved by the US Food and Drug Administration in 2010This 26-week trial compares the effectivity on glycaemic controlsafety and immunogenicity of liraglutide injection and Victoza in patients with type 2 diabetes inadequately controlled by oral metformin alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None